Dialysis & Nephrology Digest - September 2020 #2


Fresenius launches suit against Gland Pharma over pain management drug patent -

In a case before the U.S. District Court for the District of New Jersey, Fresenius alleges Gland Pharma infringed on its patent for the pain management drug Naropin when Gland applied to the FDA for an ANDA for a generic product. This despite, Fresenius contends, its patent for Naropin not scheduled to expire until May 2023. According to the complaint, Gland told the FDA “that the claims of the patent-in-suit are invalid, unenforceable and/or would not be infringed” by the proposed generic.

Please see full Publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Benesch | Attorney Advertising

Written by:


Benesch on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.